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http://dx.doi.org/1prognostic indicator in cardiovascular disease. The aim of this study was to characterize
heart rate recovery (HRR) and to determine its relation to cardiac function and morphology
in patients with hypertrophic cardiomyopathy (HC). We studied 18 healthy volunteers and
41 individuals with HC. All patients underwent clinical assessment and transthoracic
echocardiography. Continuous beat-by-beat assessment of HR was obtained during and
after cardiopulmonary exercise testing using ﬁnger plethysmography. HRR and power
spectral densities were calculated on 3 minutes of continuous RR recordings. Absolute HRR
was lower in patients than that in controls at 1, 2, and 3 minutes (25.7 – 8.4 vs 35.3 – 11.0
beats/min, p <0.001; 36.8 – 9.4 vs 53.6 – 13.2 beats/min, p <0.001; 41.2 – 12.2 vs 62.1 – 14.5
beats/min, p <0.001, respectively). HRR remained lower in patients at 2 and 3 minutes after
normalization to peak HR. After normalization to the difference in HR between peak ex-
ercise and rest, HRR was signiﬁcantly impaired in individuals with obstructive HC at
3 minutes compared with controls. HR at 3 minutes correlated with peak left ventricular
outﬂow tract gradient (B 0.154 beats/min/mm Hg, conﬁdence interval 0.010 to 0.299, p [
0.037) and remained a signiﬁcant predictor of HRR after multivariable analysis. Spectral
analysis showed a trend toward an increased low-frequency to high-frequency ratio in
patients (p[ 0.08) suggesting sympathetic predominance. In conclusion, HRR is impaired
in HC and correlates with the severity of left ventricular outﬂow tract gradient. Prospective
studies of the prognostic implications of impaired HRR in HC are warranted.  2014
Elsevier Inc. All rights reserved. (Am J Cardiol 2014;113:1011e1017)Heart rate recovery (HRR) after exercise is a product of
vagal reactivation and sympathetic withdrawal.1 Impairment
of HRR after cardiopulmonary exercise testing is associated
with increased cardiovascular and all-cause mortalities.2e7
As patients with hypertrophic cardiomyopathy (HC) have
evidence for altered autonomic function8e13 we hypothe-
sized that HRR responses are abnormal in HC. The aim of
this study was to characterize HRR responses and to
determine their relation to cardiac morphology and con-
ventional risk factors for sudden cardiac death.
Methods
The study cohort comprised 47 consecutive patients
attending a dedicated cardiomyopathy clinic at the Heart Hos-
pital, University College London Hospitals, London, UK. The
study complies with the principles of Declaration of Helsinki
andNationalHealthService researchgovernance arrangements.
Twenty healthy volunteers with no medical conditions or
family history of inherited heart disease were recruited as
controls. All participants were in sinus rhythm with no
concurrent diagnosis of anemia. One patient had type 1
diabetes mellitus. Two healthy controls were considered toiac Diseases Unit, The Heart Hospital, University College
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0.1016/j.amjcard.2013.11.062be athletically trained based on their reported level of ac-
tivity and exercise capacity (peak oxygen consumption
>170% predicted) and were excluded from subsequent
analysis. Six patients performed a submaximal exercise test
(respiratory quotient <1.05) and were excluded.
Before exercise, all patients underwent clinical assessment
using 2-dimensional transthoracic and Doppler echocardiog-
raphy, 12-lead electrocardiography, and lung spirometry. All
patients fulﬁlled current diagnostic criteria for HC based on
2-dimensional echocardiography (maximal wall thickness
15 mm unexplained by abnormal loading conditions).14
Measurement of left ventricular maximal wall thickness
(MWT), left atrial dimension, and left ventricular di-
mensions at end-systole and end-diastole was performed
using 2-dimensional echocardiography in accordance with
previously published methods.15 Ejection fraction was
calculated using Simpson’s biplane method. Left ventricular
outﬂow tract obstruction (LVOTO) was measured using
continuous wave Doppler; LVOTO was deﬁned as a resting
left ventricular outﬂow gradient of 30 or 50 mm Hg on
physiological provocation (Valsalva or exercise).
New York Heart Association functional class and the
following risk factors for sudden cardiac death were docu-
mented: nonsustained ventricular tachycardia (NSVT; 3 or
more consecutive ventricular extrasystoles at a rate of 120
beats/min) on ambulatory monitoring, unexplained syncope,
MWT 30 mm, family history of sudden cardiac death, and
an abnormal blood pressure response (ABPR) to exercise
(systolic blood pressure <20 mm Hg).14
Beta blockers and calcium channel antagonists were
withheld for at least 24 hours before exercise. Two patientswww.ajconline.org
Table 1
Baseline characteristics and recovery results from the control and disease groups
Variable Controls (n ¼ 18) All HC (n ¼ 41) Nonobstructive (n ¼ 28) Obstructive (n ¼ 13)
Men 9 36* 26* 11*
Age (yrs) 39.7  10.0 46.7  13.0* 47.5  13.7 44.9  11.8
Body mass index (kg/m2) 24.1  3.0 29.5  5.3* 29.9  5.4* 28.9  5.3*
Mean arterial blood pressure at rest (mm Hg) 90.8  7.5 92.8  12.7 94.3  12.3 89.6  13.4
Systolic blood pressure at rest (mm Hg) 120.3  10.1 124.9  18.5 127.7  16.1 118.8  22.3
Systolic blood pressure at peak (mm Hg) 165.6  21.4 169.5  30.2 171.4  28.8 165.4  33.8
Change in systolic blood pressure (mm Hg) 44.2  8.1 48.2  12.4 50.2  10.7 44.0  15.0
Active smokers 1 4 2 2
NYHA Class 1 18 22 17 5
NYHA Class 2 0 18 10 8
NYHA Class 3 0 1 1 0
Resting heart rate (beats/min) 80.5  14.7 76.6  14.51 74.6  15.8 81.1  10.6
Peak heart rate (beats/min) 176.8  18.1 149.8  21.7* 148.3  24.4* 153.0  14.7*
Change in heart rate (beats/min) 96.3  17.2 73.2  21.4* 73.8  24.2* 71.9  14.4*
Maximal oxygen consumption (ml/kg/min) 35.1  8.4 23.7  5.6* 24.2  6.1* 22.5  4.4*
Peak workload achieved (W) 206.1  73.6 143.2  47.5* 152.3  50.9* 123.5  32.5*
Maximal wall thickness (mm) — 17  [14e21] 15.0  [13e20.5] 18  [16.5e21.5]
Peak left ventricular outﬂow tract gradient (mm Hg) 6 [4e9.75] 78 [60e100.5]†
Ejection fraction (%) — 67.0  7.7 66.4  8.6 68.2  5.5
Left atrial diameter (mm) — 43.7  6.0 44.5  6.3 41.8  5
Mean heart rate at 1 minute (beats/min) 141.4  24.19 124.1  19.3* 121.9  21.5* 128.9  13.1
Mean heart rate reduction at 1 minute (beats/min) 35.3  11.0 25.7  8.4* 26.4  7.8* 24.2  9.6*
Reduction of peak heart rate at 1 minute (%) 20.4  6.8 17.2  5.2 17.9  4.8 15.6  6.0
Reduction of absolute change in heart rate during
exercise at 1 minute (%)
37.7  13.5 36.3  11.9 37.8  12.3 32.9  10.9
Mean heart rate at 2 minutes (beats/min) 123.2  25.7 113.6  17.1 110.5  18.9 118.5  11.3
Mean heart rate reduction at 2 minutes (beats/min) 53.6  13.2 36.8  9.4* 37.8  10.1* 34.5  7.5*
Reduction of peak heart rate at 2 minutes (%) 30.7  7.8 24.5  5.2* 25.4  5.4* 22.5  4.0*
Reduction of absolute change in heart rate during
exercise at 2 minutes (%)
56.6  13.9 51.7  10.9 53.2  11.9 48.4  8.0
Mean heart rate at 3 minutes (beats/min) 114.7  24.1 108.6  16.8 104.9  16.6 116.6  14.7
Mean heart rate reduction at 3 minutes (beats/min) 62.1  14.5 41.2  12.2* 43.4  12.8* 36.4  9.7*
Reduction of peak heart rate at 3 minutes (%) 35.5  8.6 27.3  6.4* 28.9  5.9* 23.8  6.2*
Reduction of absolute change in heart rate during
exercise at 3 minutes (%)
65.7  15.8 57.8  13.5 60.7  12.4 51.4  13.9*
Normalized low frequency spectral power (n.u) 0.48  0.19 0.56  0.18 0.55  0.18 0.56  0.19
Normalized high frequency spectral power (n.u) 0.51  0.19 0.44  0.18 0.45  0.18 0.44  0.19
Low:high frequency ratio 0.77 [0.53e1.93] 1.52 [0.66e2.16] 1.32 [0.68e2.14] 1.52 [0.64e2.70]
Normally distributed continuous data are expressed as mean  SD and as median and interquartile range for non-normally distributed data.
NYHA ¼ New York Heart Association.
* p <0.05 versus controls.
† p <0.05 versus nonobstructive.
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amiodarone therapy. Five patients were receiving therapy with
angiotensin-converting enzyme inhibitors, and 4 patients were
on diuretics. Only 1 patient with nonobstructive HC received
antihypertensive therapy (angiotensin-converting enzyme in-
hibitor, loop diuretic, and aldosterone antagonist) on the day of
the assessment. Exercise was performed in an upright position
using a bicycle ergometer (ergoselect 200P; Ergoline, Ger-
many) and a ramp protocol in a quiet air-conditioned room
with an average temperature of 21C and full resuscitation
facilities. Before the test, the exercise procedure was
explained, and all subjects were given the opportunity to
become familiar with the technique at zero workload. Patients
were instructed to pedal at a speed of 60 to 70 revolutions per
minute and were encouraged to exercise to maximal capacity.
Breath-by-breath gas exchange analysis was performed usinga dedicated Sensormedics metabolic cart (V Max ENCORE
229 Console; Sensormedics, Viasys Healthcare, United
Kingdom). Respiratory gases were sampled continuously
from a mouthpiece and analyzed using an electrochemical cell
oxygen analyzer and nondispersive infrared thermopile carbon
dioxide analyzer. Peak oxygen consumption (VO2), workload
(W), and respiratory exchange ratio were recorded.
Continuous beat-by-beat assessment of heart rate was
obtained using ﬁnger plethysmography (Finometer; Finapres
Medical Systems, The Netherlands). This was attached to the
index ﬁnger of the left hand and maintained in neutral posi-
tion using a specially made splint. Output was fed into a PC
running Beatscope Easy software (Finapres Medical Systems,
the Netherlands). At the point of exhaustion, the workload
was returned to zero, and individuals were requested to
remain static in an upright position for 3 minutes. HR in
Figure 1. (A) Absolute HRR after symptom limited cardiopulmonary exercise between control and HC groups. The change in mean absolute heart rate with
time after cessation of exercise is shown, with 95% CIs calculated by the Loess function. (B) HRR normalized to peak HR after symptom limited cardio-
pulmonary exercise between control and HC groups. The change in mean normalized heart rate with time after cessation of exercise is shown, with 95% CIs
calculated by the Loess function.
Cardiomyopathy/HRR in Hypertrophic Cardiomyopathy 1013recovery was analyzed as absolute HR, HR normalized to the
peak HR, and HR normalized to the change in HR from
baseline to peak exercise. HR at 1, 2, and 3 minutes during
recovery was obtained by calculating a mean HR from 10
consecutive beats at each respective time point. Analysis was
performed on the absolute HR reduction and also on the
percentage HRR standardized to peak HR and change in heart
rate between baseline and peak exercise.
Power spectral densities were calculated on 3 minutes of
continuous RR recordings obtained during recovery using
Welch, autoregressive (Levinson-Durbin algorithm), and
Lomb Scargle methods. Although absolute numbers varied,
trends and group differences were similar between methods.
Data from the Welch method are presented. Low-frequency
and high-frequency raw powers (ms2) were normalized by
total power after removal of the very low frequency compo-
nent and were expressed as normalized units (n.u). Analysis
was performed in heart rate variability (HRV) analysis soft-
ware package, 1.0.1, using MATLAB 7.12 (MathWorks,
Massachusetts).
After conﬁrmation of normality, continuous variables are
expressed as mean and SD, and categorical variables are
shown as frequencies and percentages. Frequencies were
compared using Fisher’s exact test. Comparisons between
groups were performed using independent t test and analysis
of variance test with post hoc (Bonferroni) analyses to
identify intergroup differences. Data that were not normally
distributed are expressed as median and interquartile range
and analyzed using nonparametric testing.
We sought to determine the inﬂuence of demographic
and disease-speciﬁc variables on HRR using 2 models. As
post hoc analysis identiﬁed signiﬁcant differences between
controls and patients, the ﬁrst model used multivariable
analysis with backward elimination and pooled patient andcontrol data to determine the relation of a diagnosis of HC,
gender, age, peak HR achieved, body mass index, and oxygen
consumption at peak exercise to HR at 1, 2, and 3 minutes
after exercise. To assess the inﬂuence of disease-speciﬁc
variables, a second model was constructed in the patient
group alone. A univariable analysis of 5 clinical surrogates for
disease severity—lateral E/E0, left atrial area, ejection fraction,
MWT, and left ventricular outﬂow gradient—and their rela-
tion to HR at 1, 2, and 3 minutes after exercise was performed
using linear regression. Signiﬁcant predictors were then added
to an analysis that included signiﬁcant (p <0.05) independent
predictors of HRR identiﬁed from the ﬁrst model. Statistical
comparisons were carried out using IBM SPSS Statistics,
version 20.0 and R 2.14 (CRAN.R-project.org). A p value of
<0.05 was considered signiﬁcant in all analyses.Results
The ﬁnal study cohort consisted of 18 controls and 41
patients with HC. Characteristics of the study groups are
listed in Table 1. The control group had equal numbers of
men and women, although the HC group was predominantly
men. Compared with the controls, patients were older with
higher body mass index and lower HR, oxygen consump-
tion, and workload at peak exercise. Resting HR and mean
arterial pressure were similar in both groups.
The absolute recovery in HR and HRR normalized to
peak HR is shown in Figure 1. At 1 minute, the absolute
reduction in HR was lower in the HC group (25.7  8.4 vs
35.3  11.0 beats/min, p <0.001). When normalized to
peak HR, there was a trend toward a slower recovery in HR
at 1 minute in the HC group (17.2  5.2% vs 20.4  6.8%,
p ¼ 0.052). When normalized to the change in HR from rest
to peak exercise, there was no signiﬁcant difference between
Figure 2. (A) Absolute HRR after symptom limited cardiopulmonary exercise among control, nonobstructive, and obstructive groups. The change in mean
absolute heart rate with time after cessation of exercise is shown, with 95% CIs calculated by the Loess function. (B) HRR normalized to peak HR after
symptom limited cardiopulmonary exercise among control, nonobstructive, and obstructive groups. The change in mean normalized heart rate with time after
cessation of exercise is shown, with 95% CIs calculated by the Loess function.
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0.680). At 2 minutes, the absolute reduction in HR was lower
in HC (36.8 9.4 vs 53.6 13.2 beats/min, p<0.001). This
remained signiﬁcant after normalizing to peak HR (24.5 
5.2% vs 30.7  7.8%, p ¼ 0.01). When normalized to the
change in HR from rest and peak exercise, there was no sig-
niﬁcant difference between the groups at 2 minutes (51.7 
10.9% vs 56.6  13.9%, p ¼ 0.148). At 3 minutes, the ab-
solute reduction inHR (41.2 12.2 vs 62.1 14.5 beats/min,
p <0.001) and the reduction indexed to peak HR (27.3 
6.4% vs 35.5  8.6%, p <0.001) were smaller in HC group.
When normalized to the change in HR from rest to peak ex-
ercise, there was a trend toward a lower HRR in the HC group
(57.76  13.48% vs 65.67  15.80%, p ¼ 0.054).
The characteristics of the cohort dichotomized according
to the presence or absence of a resting left ventricular
outﬂow tract gradient are listed in Table 1. Resting HR was
similar in both disease subgroups. Peak HR was higher in
controls compared with the nonobstructive and obstructive
groups. Peak oxygen capacity was higher in controls
compared with the nonobstructive and obstructive patients.
The absolute HRR and HRR normalized to peak HR are
shown in Figure 2. The absolute reduction in heart rate at
1 minute was signiﬁcantly lower in the nonobstructive
group (26.4  7.8 beats/min, p ¼ 0.007) and the obstructive
group (24.2  9.6 beats/min, p ¼ 0.005), but no difference
between the nonobstructive and obstructive groups was
observed (p ¼ 1.0). At 2 minutes, the absolute reduction in
HR was lower in the nonobstructive (37.8  10.1 beats/min,
p <0.001) and obstructive groups (34.5  7.5 beats/min,
p <0.001) compared with controls. No difference between
the nonobstructive and obstructive groups was observed
(p ¼ 1.0). A similar trend was seen at 3 minutes withabsolute HR reduction being lower in nonobstructive (43.4
 12.8 beats/min, p <0.001) and obstructive groups (36.4 
9.7 beats/min, p <0.001) versus controls. No statistical
difference was observed between obstructive and non-
obstructive patient groups (p ¼ 0.327).
When normalized to the peak heart rate, the percent
reduction in peak HR at 1 minute was similar in the control
and in the nonobstructive groups (17.9  4.8%, p ¼ 0.458).
There was a trend toward a lower HR reduction in the
obstructive group compared with the controls (15.6  6.0%,
p ¼ 0.08). There was no difference between the patient
groups (p ¼ 0.748). At 2 minutes, HRR normalized to peak
HR was lower in both nonobstructive (25.4  5.4%, p ¼
0.015) and obstructive (22.5  4.0%, p ¼ 0.01) groups
compared with controls. There was no difference between
the disease groups (p ¼ 0.478). At 3 minutes, the normal-
ized recovery in HR was lower in the nonobstructive group
(28.9  5.9%, p ¼ 0.008) and the obstructive group (23.8 
6.2%, p <0.001) compared with controls. A trend toward a
greater reduction in HR in the nonobstructive group was
observed compared with the obstructive group (p ¼ 0.09).
When HR recovery was normalized to the difference be-
tween HR at peak exercise and rest, the HRR was lower in
the obstructive group but did not reach statistical signiﬁcance
at 1 and 2 minutes. At 3 minutes, there was no signiﬁcant
difference between the controls and nonobstructive group
(p ¼ 0.726) or between the 2 disease groups (p ¼ 0.146).
There was a signiﬁcant reduction in HRR in the obstructive
group compared with the controls (p ¼ 0.019) at 3 minutes.
In model 1 incorporating controls and patients, peak HR
(B 0.911, conﬁdence interval [CI] 0.794 to 1.028, p ¼
<0.001) and HC (B 7.226, CI 1.177 to 13.276, p ¼ 0.020)
were independent predictors of HR at 1 minute. Peak HR
Figure 3. (A) Averaged low-frequency to high-frequency (LF:HF) ratio over 3 minutes between control and HC groups. Median and interquartile range. p Values
on graph. (B) Averaged LF:HF ratio over 3 minutes among control, nonobstructive, and obstructive groups. Median and interquartile range. p Values on graph.
Cardiomyopathy/HRR in Hypertrophic Cardiomyopathy 1015(B 0.803, CI 0.675 to 0.930, p <0.001) and HC (B 11.50,
CI 4.883 to 18.117, p ¼ 0.001) were also independent
predictors of HR at 2 minutes. Predictors of HR at 3 minutes
were peak HR (B 0.584, CI 0.456 to 0.712, p <0.001) and
male gender (B 13.608, CI 6.435 to 20.781, p ¼ <0.001).
In model 2 using the HC cohort alone, there was no asso-
ciation between ejection fraction and lateral E/E0 ratio with HR
during recovery. Left atrial size was a univariate predictor of
HR at 3 minutes but did not remain signiﬁcant after adjusting
for peak HR and gender. MWT was a univariate predictor of
HR at 1, 2, and 3 minutes. In multivariable analysis, MWT
(B 0.784 beats per min/mm, CI 0.078 to 1.137, p ¼ 0.026)
remained an independent predictor for HR at 1 minute after
adjusting for peak HR (B 0.608 beats/min/mm, CI 0.078 to
1.137, p ¼ 0.026). Peak LVOT gradient was a univariate pre-
dictor ofHR at 3minutes (B 0.154 beats/min/mmHg, CI 0.010
to 0.299, p ¼ 0.037). In multivariable analysis incorporating
peak left ventricular outﬂow gradient, peak HR, and gender,
peak LVOT gradient (B 0.141 beats/min/mm Hg, CI 0.059 to
0.222, p¼ 0.001) remained an independent predictor of HR at
3 minutes.
Nineteen patients had no sudden cardiac death risk fac-
tors, 13 had 1, and 9 had 2 or more. There was no associ-
ation between the number of risk factors and HRR at 1, 2,
and 3 minutes. Five patients had an ABPR to exercise, and
10 patients had NSVT. All indices of HRR were comparable
between patients with normal and ABPR to exercise (data
not shown). Patients with NSVT demonstrated a smaller
reduction in HR at 1 minute when normalized to the dif-
ference between HR at peak exercise and rest (p ¼ 0.040).
All other indices of HR recovery were comparable in pa-
tients with and without NSVT (data not shown).
During the 3 minutes of recovery, the low-frequency and
high-frequency componentswere similar between controls and
patients (Table 1). The low-frequency to high-frequency ratio
was higher in the combined HC group compared the controlswith a trend toward signiﬁcance (p ¼ 0.08; Figure 3).
Dichotomization of the HC group by obstruction failed to
identify any signiﬁcant difference among the 3 groups (Table 1
and Figure 3).
Discussion
In large follow-up studies of healthy adults, impaired HR
recovery has been shown to be a predictor of all-cause
mortality and, in individuals with cardiac disease, is asso-
ciated with an increased risk of cardiac and all-cause mor-
talities.2e7 HRR after exercise results from the combined
effects of sympathetic withdrawal and parasympathetic
reactivation. Although published data are not entirely
consistent, studies using parasympathetic and b-adrenergic
blockade suggest that the restoration of parasympathetic
tone predominates in early HR recovery after exercise in
both health and disease.16 However, the explanation for the
association between abnormal HR recovery and an
increased risk of death in various settings is not known.
The results of this study demonstrate that HR recovery is
impaired in patients with HC, and that LVOTO is a key
determinant of the HRR response. Although there is some
variability in the ﬁndings of individual studies, most data
suggest that autonomic function is abnormal in patients with
HC, with the majority showing decreased cardiac para-
sympathetic activity.8e10 The evidence in support of altered
sympathetic activity in HC is less consistent with studies
showing a reduction in sympathetic tone during activities of
daily living and an increase in sympathetic tone in patients
with advanced disease.11,12 A number of studies have also
shown that local cardiac noradrenaline kinetics are altered with
reduced synaptic re-uptake, increased myocardial washout
rate, and a reduction in b adrenergic receptor density.17e20
Few studies have speciﬁcally examined autonomic function
during exercise in patients with HC, but it is suggested that
1016 The American Journal of Cardiology (www.ajconline.org)the common ﬁndings of ABPR on exercise21e24 may be
explained by peripheral vasodilation caused by inappropriate
ﬁring of cardiopulmonary mechanoreceptors during central
blood volume unloading.25,26
We postulate that individuals with HC have a reduction
in the vagal inﬂuences that determine heart rate kinetics. The
association between LVOTO and HRR may be explained by
a reduction in arterial baroreceptor stimulation during late
systole as a result of altered aortic pressure. Alternatively, it
may represent a paradoxical and compensatory response to a
reduction in peripheral resistance after activation of car-
diopulmonary mechanoreceptors in response to the ven-
tricular stretch and myocardial ischemia generated by
LVOTO. Although the data in this study are consistent with
abnormal sympathovagal balance after exercise, analysis of
the frequency power spectrum only showed a trend toward
signiﬁcance between the control and the combined HC
group. Technical limitations have to be considered,
including signal noise and artifact that may have been
introduced by the recording technique and exaggerated by
the short sampling duration. The power spectrum was not
assessed during exercise, and environmental factors that can
disturb sympathovagal balance and the inﬂuence of respi-
ratory rate on the power spectrum were not accounted for. In
addition, HRV may not linearly reﬂect parasympathetic
outﬂow, and saturation of parasympathetic tone may reduce
the respiratory variation on heart rate and thus HRV.27,28
Physiological and withdrawal effects of cardioactive medi-
cations may also persist beyond the time frame chosen in
this study, and dietary intake for and the timing of the ex-
ercise test were not accounted for. Finally, the use of ﬁnger
plethysmography may not be accurate at determining the
presence of ectopy and atrial arrhythmias. However, we
found that ﬁnger plethysmography with the use of a splint to
maintain the hand in a neutral position was less prone to
movement artifact than the surface electrocardiogram during
dynamic exercise, and no patient developed atrial or ven-
tricular arrhythmias during exercise.Disclosures
The authors have no conﬂicts of interest to disclose.
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